However, there are two crucial differences between the companies right now. Full-Year 2024 Guidance In November In January In May Reported sales growth 0.5% to 6.5% 0.5% to 6.5% (4%) to (6%) Organic sales growth (2%) to 4% (2%) to 4% (6%) to (8%) Adjusted EPS $12-$13.50 $12-$13.50 $10-$11 A more resilient business model Another reason to favor PTC is its more resilient business model. For example, it's harder for Rockwell to cut costs in a downturn, meaning that its profit margin will dip when sales start t ...

WARREN, N.J., June 21, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 17, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,380 shares of its common stock and 6,260 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to nine new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The ...

--New App Empowers Engineers and Designers to Validate Manufacturability, Optimize Designs, and Accelerate Speed to Market-- --Leverages Proprietary Artificial Intelligence (AI) Algorithms-- ITASCA, Ill., June 10, 2024 /PRNewswire/ -- SyBridge Technologies, a global leader in design and manufacturing solutions, today announced the launch of SyBridge Studio, a state-of-the-art manufacturing insights application, now available on the PTC Onshape® App Store. This advanced tool integrates a comprehensive suite ...

WARREN, N.J., May 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: William Blair's 44th Annual Growth Stock Conference Tuesday, June 4, at 9:00 am ET / 8:00 am CT The presentation will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It ...

- Review of European marketing application for PKU now initiated - WARREN, N.J., May 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA. "The validation of the MAA is an important step towards making sepiapterin available to children and adults affected by PKU in Europe," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "The European submission is the first of several g ...

PTC Inc (PTC) is continuing its upward trajectory, with a gain of 41% in the past year compared with the S&P 500 composite and sub-industry's growth of 29.2% and 35.7%, respectively. PTC is a software provider offering a comprehensive portfolio of software including computer-aided design (CAD) and product lifecycle management (PLM) solutions. The company's software can be delivered on- premises, in the cloud or in a hybrid model. Solid financial performance has been driving a good run on the trading front. ...

WARREN, N.J., May 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation. As a result, Translarna remains on the market and available for patients in Europe consistent with its current marketing authorization. The EC has asked the ...

The industrial software company's recent results gave investors confidence in it hitting its full-year guidance.Industrial software company PTC's (PTC) stock has dipped recently, and investors, initially at least, reacted negatively to the company's fiscal second-quarter earnings, which it released at the start of May. Is the trend likely to continue, or is now an excellent time to pick up stock in an exciting growth company?PTC's recent big newsInvestors usually pencil in assumptions for medium-term growth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_ to_ Commission File Number: 0-18059 Securities registered pursuant to Section 12(b) of the Act: PTC Inc. | Title of each class | Trading symbol(s) | Name of each exchan ...

PTC Inc. (PTC) reported second-quarter fiscal 2024 non-GAAP earnings per share (EPS) of $1.46, up 26% on a year-over-year basis. Also, the figure surpassed the Zacks Consensus Estimate by 18.7%.Revenues came in at $603 million, up 11% year over year (up 11% at constant currency or cc). The top line beat the Zacks Consensus Estimate by 4.8%.The year-over-year improvement in the top line was driven by steady demand for its computer-aided design (CAD) and product lifecycle management (PLM).Top Line in DetailRe ...